NasdaqGS - Nasdaq Real Time Price USD

Kezar Life Sciences, Inc. (KZR)

0.8049

+0.0149

(+1.89%)

At close: April 26 at 4:00 PM EDT

0.8078

+0.00

(+0.36%)

After hours: April 26 at 7:38 PM EDT

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin. The markets were off to an impressive start in 2024, driven by expectations that the […]

Insider Monkey 18 days ago

FPH

ARAY

DNN
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2

Business Wire 18 days ago

KZR
+1.89%
From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

A constellation of stocks beckons daring investors from the great expanse of the financial galaxy, where stars glitter with promise and fortunes wait to be discovered. The first stop on the journey is a celestial body whose excellent recovery rates and record-breaking throughput suggest a gold mine of opportunities. Travelers discover the keys of management skill and operational excellence that drive its growth as they navigate its glistening expanse. However, the journey doesn’t end there. Inst

InvestorPlace 30 days ago

KZR
+1.89%
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026

Penny stocks provide risk and profit but frequently lie in the shadows in the fast-paced world of investing. Nevertheless, three-penny stocks stand like diamonds in the dust among the chaos and uncertainties. These companies have the potential to reach previously unheard-of heights and anticipate a 500% increase in revenue by 2026. These stocks are more than simply wild speculations. They are well-thought-out examples of successful market penetration tactics, solid financial relationships and st

InvestorPlace last month

KZR
+1.89%
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Business Wire last month

KZR
+1.89%
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., February 28, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate on the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health Care Conference. The panel will be held on Tuesday, March 5, 2024, at 10:30 a.m. ET.

Business Wire last month

KZR
+1.89%
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

SHANGHAI & SOUTH SAN FRANCISCO, Calif., February 26, 2024--Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN). Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor

Business Wire last month

1952.HK

KZR
+1.89%
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

In almost every situation, investors should stay away from penny stocks. They’re extremely speculative and they tend to facilitate delusions of grandeur. To be sure, there’s nothing wrong with hope. But hope shouldn’t be a substitute for sound research and due diligence. Still, it’s also possible – in some limited sense – that you miss 100% of the shots you don’t take. Granted, I’ve got to be careful with this statement. If you take the shots, you’re more likely to miss than hit and those misses

InvestorPlace last month

TNXP

BLRX

KZR
+1.89%
3 Penny Stocks Poised for an Unbelievable 1,000% Jump

In stock markets, uncovering penny stocks with a 10X boost potential is rare, but possible. This requires the identification of extraordinary growth potency. Among the multitude of stocks, three penny stocks are quietly positioning themselves for an unbelievable surge, potentially reaching a staggering 1,000%. Read more to dissect why they might be the untapped treasures that redefine investment returns. 8×8 (EGHT) Source: fizkes / Shutterstock.com For 8×8 (NASDAQ:EGHT), revenue growth and produ

InvestorPlace 2 months ago

SNDL

KZR
+1.89%
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth

In the labyrinth of the stock market, discovering penny growth stocks often promises exhilarating prospects. This article navigates through the tumultuous waves of investment options, spotlighting three promising penny stocks. These companies illuminate diverse sectors: biotechnology, information technology, and autonomous vehicles, respectively. The first one’s pioneering clinical trials target autoimmune diseases and oncologic disorders. Meanwhile, the second one’s robust financial performance

InvestorPlace 4 months ago

KZR
+1.89%
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif., November 21, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL.

Business Wire 5 months ago

KZR
+1.89%
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., November 13, 2023--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire 5 months ago

KZR
+1.89%
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic ...

ACCESSWIRE 5 months ago

KZR
+1.89%
AVIR

BOLT
12 Best Penny Stocks to Buy Under $1

In this article, we will take a look at the 12 best penny stocks to buy under $1. To see more such companies, go directly to 5 Best Penny Stocks to Buy Under $1. Investors are optimistic as we move into the third quarter earnings season. Hopes in the Wall Street are growing that we […]

Insider Monkey 6 months ago

NVTA

AMRN

CMRX
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Zacks 6 months ago

KZR
+1.89%
CORT

ANVS
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

SOUTH SAN FRANCISCO, Calif., October 03, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment is expected to extend operating capital to fund PALIZADE, Kezar’s Phase 2b clinical trial in lupus nephritis.

Business Wire 6 months ago

KZR
+1.89%
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

SOUTH SAN FRANCISCO, Calif., September 20, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today announced that it entered into a collaboration and license agreement with Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, to develop and commercialize zetomipzomib, Kezar’s

Business Wire 7 months ago

KZR
+1.89%
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., August 31, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September:

Business Wire 7 months ago

KZR
+1.89%
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., August 10, 2023--Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Business Wire 8 months ago

KZR
+1.89%
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., August 04, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase 66,000 shares of its common stock with an exercise price of $2.19 per share, which is equal to the closing price of Kezar’s common

Business Wire 8 months ago

KZR
+1.89%

Performance Overview

Return	KZR	S&P 500
YTD	-15.27%	+6.92%
1-Year	-67.15%	+25.26%
3-Year	-85.85%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kezar Life Sciences, Inc. (KZR)

13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

From Pennies to Fortunes: 3 Stocks Set to Make Millionaires

Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

3 Penny Stocks Poised for an Unbelievable 1,000% Jump

Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

12 Best Penny Stocks to Buy Under $1

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Performance Overview